Doxorubicin

This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80168379AG, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but generally known as doxorubicin, which bears US NIH Compound Identifier 1691. European Medicines Agency schedules Doxorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG. The term DOXORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules doxorubicin in its Anatomical Therapeutic Chemical (ATC) Classification. DOXORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxorubicin under HS 29419000 and SITC 54139. As of Q4 2014, DOXORUBICIN remains the US FDA Preferred Term for this commodity. Doxorubicin bears US NLM identifiers UMLS ID C0013089 and NCI Concept Code C456. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO)C1OC(C(O)C(N)C1)C.